Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine vs Megestrol Acetate for Cancer-Associated Anorexia
NCT04939090Phase 3Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jan 2022
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of olanzapine in anorexia nervosa (AN) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Change in appetite at 4 weeks. Started Jan 2022; status: active, not recruiting.
02
Drugs
olanzapine
03
Conditions
anorexia nervosa (AN)
Beyond the preview
Go deeper on NCT04939090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939090.